| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Myristyl dimethylamine oxide does not have a defined pharmacological target as it is a surfactant rather than a therapeutic drug. As an amine oxide, it interacts with lipid membranes and interfaces through its amphiphilic properties, reducing surface tension and providing antistatic effects. In research applications, it may be used as a biochemical reagent to study membrane interactions, protein solubilization, or as a component of cell culture media formulations.
|
|---|---|
| ln Vitro |
A biochemical reagent called myristyl dimethylamine oxide can be utilized in life science research as an organic compound or biological material.
No specific in vitro pharmacological activity data are available for myristyl dimethylamine oxide as a drug candidate. As a biochemical reagent, it is used in life science research as an organic compound or biological material. Its surfactant properties make it useful for studies involving membrane protein extraction, cell lysis, and formulation development. In vitro activity is typically assessed based on surface tension reduction, viscosity enhancement, and foaming characteristics rather than pharmacological endpoints. |
| ln Vivo |
No specific in vivo pharmacological activity data have been documented for myristyl dimethylamine oxide as a therapeutic agent. The compound is primarily used in personal care and household cleaning product formulations rather than in animal research. If used in animal studies, it would be formulated using appropriate vehicles such as DMSO-based solutions. Dosing and administration protocols would need to be established based on the specific research objectives.
|
| Enzyme Assay |
For non-cellular biochemical assays, myristyl dimethylamine oxide can be evaluated for its surfactant properties including surface tension measurement using a tensiometer, critical micelle concentration determination, and foaming capacity assessment. Standard protocols involve preparing serial dilutions of the compound in aqueous buffer and measuring surface tension at room temperature. Viscosity measurements can be performed using a viscometer. These assays are typically conducted at concentrations ranging from 0.01% to 10% depending on the application.
|
| Cell Assay |
For in vitro cell-based studies, myristyl dimethylamine oxide can be dissolved in DMSO or aqueous buffers and diluted in cell culture medium. Cells are cultured under standard conditions and treated with the compound at various concentrations to assess cytotoxicity, membrane permeability, or other cellular responses. Due to its surfactant nature, the compound may affect cell membrane integrity at higher concentrations. Appropriate controls and concentration ranges should be determined empirically for each cell type.
|
| Animal Protocol |
For in vivo animal studies, myristyl dimethylamine oxide can be formulated using standard injection vehicles such as DMSO:Tween 80:saline mixtures. The compound powder should be stored at -20°C for up to 3 years or at 4°C for up to 2 years; in solvent, it is stable at -80°C for 6 months or at -20°C for 1 month. The product should be stored in a sealed environment away from moisture. Dosing and administration should follow approved animal protocols.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of myristyl dimethylamine oxide are not well characterized as it is a surfactant rather than a pharmaceutical. The compound has a logP of 5.282, indicating high lipophilicity. It has 0 hydrogen bond donors, 1 hydrogen bond acceptor, and 13 rotatable bonds. Storage: powder at -20°C for 3 years, 4°C for 2 years; in solvent at -80°C for 6 months or -20°C for 1 month. Protect from moisture during storage. Solubility may be tested in DMSO, water, ethanol, or DMF.
|
| Toxicity/Toxicokinetics |
Toxicological data for myristyl dimethylamine oxide are limited. As a surfactant used in personal care products, it is generally considered to have low acute toxicity at typical use concentrations. The compound is for research use only and not for human therapeutic applications. Standard laboratory safety practices should be followed. Specific LD50 values and detailed toxicological profiles have not been extensively reported in the pharmaceutical literature.
|
| Additional Infomation |
Myristyl dimethylamine oxide (CAS 3332-27-2) is a cationic surfactant of the amine oxide family. It is also known as N,N-dimethyltetradecan-1-amine oxide and has the SMILES structure CCCCCCCCCCCCCC[N+]([O-])(C)C. The compound is used as a foam booster, thickener, conditioner, and antistatic agent in personal care and cleaning products. No clinical trials or regulatory approvals for human therapeutic use exist. The product is supplied as a research-grade biochemical reagent.
|
| Molecular Formula |
C16H35NO
|
|---|---|
| Molecular Weight |
257.46
|
| Exact Mass |
257.272
|
| CAS # |
3332-27-2
|
| PubChem CID |
18739
|
| Appearance |
White to off-white solid powder
|
| LogP |
5.282
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
18
|
| Complexity |
169
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCCCC[N+]([O-])(C)C
|
| InChi Key |
ONHFWHCMZAJCFB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H35NO/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17(2,3)18/h4-16H2,1-3H3
|
| Chemical Name |
N,N-dimethyltetradecan-1-amine oxide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8841 mL | 19.4205 mL | 38.8410 mL | |
| 5 mM | 0.7768 mL | 3.8841 mL | 7.7682 mL | |
| 10 mM | 0.3884 mL | 1.9420 mL | 3.8841 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
